A ntitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
OncoTargets and Therapy, ISSN: 1178-6930, Vol: 7, Page: 697-702
2014
- 7Citations
- 21Captures
Metric Options: Counts3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of gastrointestinal stromal tumor and also in several cases of acral and mucosal melanomas. Some of the patients with gastrointestinal stromal tumor or melanoma harboring this rare mutation have had a tumor response when treated with imatinib. In contrast, in our case, the mutation was associated with primary resistance to full doses of imatinib but, at the same time, it was not a cause of resistance to sorafenib. © 2014 Mirtavoos-Mahyari et al.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84900400930&origin=inward; http://dx.doi.org/10.2147/ott.s58902; http://www.ncbi.nlm.nih.gov/pubmed/24855380; http://www.dovepress.com/antitumor-activity-of-sorafenib-and-imatinib-in-a-patient-with-thymic--peer-reviewed-article-OTT; https://www.dovepress.com/getfile.php?fileID=19965; https://dx.doi.org/10.2147/ott.s58902; https://www.dovepress.com/antitumor-activity-of-sorafenib-and-imatinib-in-a-patient-with-thymic--peer-reviewed-fulltext-article-OTT
Dove Medical Press Ltd.
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know